Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

Biological inventions – EPO Enlarged Board of Appeal faced the second time with the tomato case (EPLAW) (IPKat)

No new moves to compulsory licensing in China, say experts (IAM) (China Hearsay)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

National Association of Boards of Pharmacy applies for new gTLD .pharmacy (The Domains)

Canada: Several provinces express concern over CETA IP provisions and potential increase in drug costs (Michael Geist)

China: No new moves to compulsory licensing in China, say experts (IAM) (China Hearsay)

China: IP key to the rise and rise of the Chinese pharma sector (IAM)

EU: Biological inventions – EPO Enlarged Board of Appeal faced the second time with the tomato case (EPLAW) (IPKat)

India: From the archives: The lobbying briefs of the IDMA, IPA, OPPI & ICPA for the Patent (Amendment) Acts of 1999 & 2002 (Spicy IP)

Spain: TRIPS and trade winds:Spanish injunctions and chemical-pharmaceutical patents (PatLit)

US: Plaintiffs respond to Myriad’s “suggestion” of mootness or, alternatively, motion for remand in AMP v. USPTO (Patent Docs)

US: Troll Busters’ attack on nucleic acid patent one of the reexamination requests filed week of June 4, 2012 (WHDA)

US: Does patenting alienate customers? Genome sequencing company, 23andme gets first US patent (IPKat)

US: Another look at IPO top 300 and life sciences top 53 (Patent Docs)

US: Human Genome Sciences files for review of PTA calculation for patent entitled “Methods of inhibiting B lymphocytes using antibodies to neutrokine-alpha” (Patent Docs)

US: FDA should be required to provide 510(k) decision summaries (FDA Law Blog)

 

Products

Abilify (Aripiprazole) – Australia: FCA: Generic Abilify ban to be reviewed: Generic Health v Otsuka (Patentology)

Abilify (Aripiprazole) – US: CAFC: “Lead compound” approach to obviousness and obviousness-type double patenting: Otsuka v Sandoz (PharmaPatents)

Altace (Ramipril) – Canada: Ramipril section 8 damages – distinct “but for” worlds for each generic (Beeser Ramamoorthy)

Copaxone (Glatiramer) – UK: EWCA (Civ) allows appeal against decision of Patents Court to ban involvement of appellant’s IP Director from acting in patent litigation between the parties: Generics (UK) t/a Mylan v Yeda R&D and Teva (EPLAW) (Out-Law)

Daivonex (Calcipotriol) – Germany: Federal Court of Justice revokes Leo’s calcipotriol monohydrate patent (Kluwer Patent Blog)

Emend (Fosaprepitant dimeglumine) – US: Merck Sharp and Dohme files patent infringement suits against Accord Healthcare and Sandoz following Para IV certification filing (Patent Docs)

Hectorol (Doxercalciferol) – US: District Court Delaware finds inducement of infringement in Doxercalciferol: Bone Care v Roxane (Orange Book Blog)

Herceptin (Trastuzumab) – US: Genentech and University of Pennsylvania settle Herceptin patent suit (Beeser Ramamoorthy)

Lunesta (Eszoplicone) – US: Motivation to resolve enantiomers: District of New Jersey decision in Sunovion v Teva (Beeser Ramamoorthy)

Mevacor (Lovastatin) – Canada: Apotex partly denied section 8 claim on basis of ex turpi causa principle: Apotex v Merck (Beeser Ramamoorthy)

Neupogen (Filgrastim) – Canada: On your mark, get set, go! Biosimilar litigation takes off in Canada: Amgen v Teva (Beeser Ramamoorthy)

Niaspan (Niacin) – US: Abbott files patent infringement suit against Kremers Urban Pharmaceuticals in response to Para IV challenge (Patent Docs)

PetArmor (Fipronil) – US: Merial files patent infringement complaint against Valcera and Fidopharm in MD Georgia; Fidopharm files for declaratory judgment of non-infringement and invalidity against Merial in Delaware (Patent Docs)

Solodyn (Minocycline) – US: Medicis files patent infringement complaints against Zydus in Delaware and New Jersey in response to Para IV challenge (Patent Docs)